Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC and PD-L1 Expression in Gastric Cancer With Peritoneal Metastases
NCT04107077Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Sep 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and mitomycin c in gastric cancer (GC), sponsored by University of Chicago. Primary endpoint: PD-L1 expression upregulation frequency at 2 years. Started Sep 2025; status: recruiting.
02
Drugs
cisplatinmitomycin c
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04107077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04107077.